Altium Capital Management LP Cytom X Therapeutics, Inc. Transaction History

Altium Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.53 - $2.89 $1.02 Million - $1.92 Million	-663,800 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $2.21 Million - $4.21 Million	-569,842 Reduced 46.19%	663,800 $2.87 Million
Q3 2021 Nov 15, 2021	BUY	$4.32 - $6.43 $1.6 Million - $2.39 Million	371,225 Added 43.04%	1,233,642 $7.46 Million
Q2 2021 Aug 13, 2021	BUY	$6.33 - $9.91 $2.4 Million - $3.76 Million	379,376 Added 78.54%	862,417 $5.46 Million
Q1 2021 May 06, 2021	BUY	$6.6 - $9.0 $1.38 Million - $1.88 Million	209,338 Added 76.48%	483,041 $3.73 Million
Q4 2020 Feb 16, 2021	BUY	$6.47 - $7.9 $1.77 Million - $2.16 Million	273,703 New	273,703 $1.79 Million

50.2M

22.3K

22.9K

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $79.1M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

Get notified when there are updates to the investment portfolio of Altium Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Altium Capital Management LP with notifications on news.